<DOC>
	<DOC>NCT01129024</DOC>
	<brief_summary>This is a Phase 2, multicenter, open-label, dose-ranging, parallel-group extension study to evaluate the safety of S-888711 in the treatment of subjects with immune thrombocytopenia. Patients who participate in this study must have completed the Phase 2 double-blind, randomized controlled study.</brief_summary>
	<brief_title>An Open-label Safety Study of S-888711</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>A signed and dated written informed consent Males and females â‰¥ 18 years of age All subjects must agree to use barrier contraception Diagnosis of ITP Subjects &gt; 60 years must have had a diagnostic bone marrow aspiration Relapsed persistent or chronic ITP status Subjects receiving steroid therapy must be on a stable dose PT and APTT within 20% of the upper limit of normal Subjects receiving stable dosages of cyclosporine A, mycophenolate mofetil, azathioprine, or danazol are allowed History of clinically important hemorrhagic clotting disorder Females who are pregnant, lactating, or taking oral contraceptives History of alcohol/drug abuse or dependence within 1 year Use of the following drugs or treatment prior to Visit 1 (Day 1): Within 1 week Rho(D) immune globulin or intravenous immunoglobulin; Within 2 weeks plasmaphoresis treatment; Within 4 weeks use of antiplatelet or anticoagulant drugs; Within 8 weeks rituximab; Within 12 weeks alemtuzumab, multidrug systemic chemotherapy, stem cell therapy; History of clinically significant cardiovascular or thromboembolic disease within 26 weeks prior to Initial Screening Splenectomy within 4 weeks prior to Initial Screening Clinically significant laboratory abnormalities Hemoglobin &lt; 10.0 g/dL for men or women, not clearly related to ITP Absolute neutrophil count &lt; 1000/mm3 Abnormal peripheral blood smear with evidence of fibrosis confirmed by bonemarrow biopsy Total bilirubin &gt; 1.5 x upper limit of normal Alanine aminotransferase (ALT) &gt; 1.5 x upper limit of normal Aspartate aminotransferase (AST) &gt; 1.5 x upper limit of normal Creatinine &gt; 1.5 x upper limit of normal Human immunodeficiency virus positive Hepatitis A IgM antibody positive, hepatitis B surface antigen or hepatitis C antibody positive Exposure to previous TPO mimetics/agonists (e.g., eltrombopag,romiplostim, E5501 [AKR501] or LGD4665) within 4 weeks prior to Initial Screening Subjects unresponsive to previous TPO mimetics/agonists (e.g., eltrombopag, romiplostim, E5501 [AKR501] or LGD4665) Exposure to an investigative medication within 4 weeks prior to the initial Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Splenectomy</keyword>
	<keyword>Low Platelet Count</keyword>
	<keyword>Thrombopoiesis</keyword>
	<keyword>Thrombocytopaenia</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Immune Thrombocytopenia (ITP)</keyword>
	<keyword>Thrombotic Thrombocytopenic Purpura (ITP)</keyword>
	<keyword>Hematologic Disease</keyword>
	<keyword>Auto-immune Thrombocytopenic Purpura</keyword>
	<keyword>S-888711</keyword>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Relapsed Persistent or Chronic ITP</keyword>
	<keyword>ITP</keyword>
</DOC>